Jpmorgan Chase & CO Cyclerion Therapeutics, Inc. Transaction History

Jpmorgan Chase & CO

  • $1.14 Trillion
  • Q2 2024

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2021

Feb 10, 2022
SELL
$1.56 - $2.99 $64,479 - $123,585
-41,333 Closed
0 $0
Q3 2021

Nov 12, 2021
BUY
$2.73 - $4.13 $112,839 - $170,705
41,333 New
41,333 $127,000

Others Institutions Holding CYCN

# of Institutions
1
Shares Held
293K
Call Options Held
0
Put Options Held
0
View Full List

About Cyclerion Therapeutics, Inc.

CYCN Quotes by TradingView
  • Ticker CYCN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 43,479,800
  • Market Cap $153M
  • Description
  • Cyclerion Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering, development, and commercialization of medicines for serious central nervous system (CNS) diseases. Its lead product candidate is CY6463, a CNS-penetrant, soluble guanylate cyclase (sGC) stimulator that is in Phase IIa trials for the treatment of...
More about CYCN
Track This Portfolio

Track Jpmorgan Chase & CO Portfolio

Follow Jpmorgan Chase & CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

News

Stay updated on Jpmorgan Chase & CO with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email